The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206

References

• Konicek BW, Dumstorf CA, Graff JR. Targeting the eIF4F translation initiation complex for cancer therapy. Cell Cycle 2008; 7:2466-71; PMID:18719377; http://dx.doi.org/10.4161/cc.7.16.6464
   PubMed Web of Science ®Google Scholar
• Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer 2010; 10:254-66; PMID:20332778; http://dx.doi.org/10.1038/nrc2824
   PubMed Web of Science ®Google Scholar
• De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004; 23:3189-99; PMID:15094768; http://dx.doi.org/10.1038/sj.onc.1207545
   PubMed Web of Science ®Google Scholar
• Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009; 136:731-45; PMID:19239892; http://dx.doi.org/10.1016/j.cell.2009.01.042
   PubMed Web of Science ®Google Scholar
• Kerekatte V, Smiley K, Hu B, Smith A, Gelder F, De Benedetti A. The proto-oncogenetranslation factor eIF4E: a survey of its expression in breast carcinomas. Int J Cancer 1995; 64:27-31; PMID:7665244; http://dx.doi.org/10.1002/ijc.2910640107
   PubMed Web of Science ®Google Scholar
• Rosenwald IB, Chen JJ, Wang S, Savas L, London IM, Pullman J. Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 1999; 18:2507-17; PMID:10229202; http://dx.doi.org/10.1038/sj.onc.1202563
   PubMed Web of Science ®Google Scholar
• Wang S, Rosenwald IB, Hutzler MJ, Pihan GA, Savas L, Chen JJ, Woda BA. Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas. Am J Pathol 1999; 155:247-55; PMID:10393856; http://dx.doi.org/10.1016/S0002-9440(10)65118-8
   PubMed Web of Science ®Google Scholar
• Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS, McNulty AM, Parsons SH, Brail LH, Colligan BM, Koop JW, et al. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res 2009; 69:3866-73; PMID:19383915; http://dx.doi.org/10.1158/0008-5472.CAN-08-3472
   PubMed Web of Science ®Google Scholar
• Wang R, Geng J, Wang JH, Chu XY, Geng HC, Chen LB. Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma. Lung Cancer 2009; 66:237-44; PMID:19261348; http://dx.doi.org/10.1016/j.lungcan.2009.02.001
   PubMed Web of Science ®Google Scholar
• Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, Baselga J, Ramon Y Cajal S. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 2007; 67:7551-5; PMID:17699757; http://dx.doi.org/10.1158/0008-5472.CAN-07-0881
   PubMed Web of Science ®Google Scholar
• Rojo F, Najera L, Lirola J, Jimenez J, Guzman M, Sabadell MD, Baselga J, Ramon Y Cajal S. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 2007; 13:81-9; PMID:17200342; http://dx.doi.org/10.1158/1078-0432.CCR-06-1560
   PubMed Web of Science ®Google Scholar
• Noske A, Lindenberg JL, Darb-Esfahani S, Weichert W, Buckendahl AC, Roske A, Sehouli J, Dietel M, Denkert C. Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol Rep 2008; 20:1409-17; PMID:19020722
   PubMed Web of Science ®Google Scholar
• Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature 1990; 345:544-7; PMID:2348862; http://dx.doi.org/10.1038/345544a0
   PubMed Web of Science ®Google Scholar
• Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, Pandolfi PP. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004; 10:484-6; PMID:15098029; http://dx.doi.org/10.1038/nm1042
   PubMed Web of Science ®Google Scholar
• Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428:332-7; PMID:15029198; http://dx.doi.org/10.1038/nature02369
   PubMed Web of Science ®Google Scholar
• Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, Gross JD, Degterev A, Yuan J, Chorev M, et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 2007; 128:257-67; PMID:17254965; http://dx.doi.org/10.1016/j.cell.2006.11.046
   PubMed Web of Science ®Google Scholar
• Fan S, Li Y, Yue P, Khuri FR, Sun SY. The eIF4EeIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. Neoplasia 2010; 12:346-56; PMID:20360945
   PubMed Web of Science ®Google Scholar
• Chen L, Aktas BH, Wang Y, He X, Sahoo R, Zhang N, Denoyelle S, Kabha E, Yang H, Freedman RY, et al. Tumor suppression by small molecule inhibitors of translation initiation. Oncotarget 2012; 3:869-81; PMID:22935625
   PubMed Web of Science ®Google Scholar
• Descamps G, Gomez-Bougie P, Tamburini J, Green A, Bouscary D, Maiga S, Moreau P, Le Gouill S, Pellat-Deceunynck C, Amiot M. The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction. Br J Cancer 2012; 106:1660-7; PMID:22510748; http://dx.doi.org/10.1038/bjc.2012.139
   PubMed Web of Science ®Google Scholar
• Hoeffer CA, Cowansage KK, Arnold EC, Banko JL, Moerke NJ, Rodriguez R, Schmidt EK, Klosi E, Chorev M, Lloyd RE, et al. Inhibition of the interactions between eukaryotic initiation factors 4E and 4G impairs long-term associative memory consolidation but not reconsolidation. Proc Natl Acad Sci U S A 2011; 108:3383-8; PMID:21289279; http://dx.doi.org/10.1073/pnas.1013063108
   PubMed Web of Science ®Google Scholar
• McMahon R, Zaborowska I, Walsh D. Noncytotoxic inhibition of viral infection through eIF4F-independent suppression of translation by 4EGi-1. J Virol 2011; 85:853-64; PMID:21068241; http://dx.doi.org/10.1128/JVI.01873-10
   PubMed Web of Science ®Google Scholar
• Hoeffer CA, Santini E, Ma T, Arnold EC, Whelan AM, Wong H, Pierre P, Pelletier J, Klann E. Multiple components of eIF4F are required for protein synthesis-dependent hippocampal long-term potentiation. J Neurophysiol 2013; 109:68-76; PMID:23054596; http://dx.doi.org/10.1152/jn.00342.2012
   PubMed Web of Science ®Google Scholar
• Santini E, Huynh TN, MacAskill AF, Carter AG, Pierre P, Ruggero D, Kaphzan H, Klann E. Exaggerated translation causes synaptic and behavioural aberrations associated with autism. Nature 2013; 493:411-5; PMID:23263185; http://dx.doi.org/10.1038/nature11782
   PubMed Web of Science ®Google Scholar
• Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci U S A 2004; 101:18105-10; PMID:15601771; http://dx.doi.org/10.1073/pnas.0406927102
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj A, Liu Y, et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 2010; 328:1172-6; PMID:20508131; http://dx.doi.org/10.1126/science.1187532
   PubMed Web of Science ®Google Scholar
• Yellen P, Saqcena M, Salloum D, Feng J, Preda A, Xu L, Rodrik-Outmezguine V, Foster DA. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 2011; 10:3948-56; PMID:22071574; http://dx.doi.org/10.4161/cc.10.22.18124
   PubMed Web of Science ®Google Scholar
• Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004; 166:213-23; PMID:15249583; http://dx.doi.org/10.1083/jcb.200403069
   PubMed Web of Science ®Google Scholar
• O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-8; PMID:16452206; http://dx.doi.org/10.1158/0008-5472.CAN-05-2925
   PubMed Web of Science ®Google Scholar
• Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65:7052-8; PMID:16103051; http://dx.doi.org/10.1158/0008-5472.CAN-05-0917
   PubMed Web of Science ®Google Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58:621-81; PMID:16968952; http://dx.doi.org/10.1124/pr.58.3.10
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70:440-6; PMID:20068163; http://dx.doi.org/10.1158/0008-5472.CAN-09-1947
   PubMed Web of Science ®Google Scholar
• Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10:307-18; PMID:19339977; http://dx.doi.org/10.1038/nrm2672
   PubMed Web of Science ®Google Scholar
• Appenzeller-Herzog C, Hall MN. Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling. Trends Cell Biol 2012; 22:274-82; PMID:22444729; http://dx.doi.org/10.1016/j.tcb.2012.02.006
   PubMed Web of Science ®Google Scholar
• Leontieva OV, Demidenko ZN, Blagosklonny MV. Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium. Cell Death Dis 2014; 5:e1214; PMID:24810050; http://dx.doi.org/10.1038/cddis.2014.178
   PubMed Web of Science ®Google Scholar
• Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptorinsulin receptor substrate-11487;phosphatidylinositol 3-kinase cascade. Mol Cancer Therapeut 2005; 4:1533-40; PMID:16227402; http://dx.doi.org/10.1158/1535-7163.MCT-05-0068
   PubMed Web of Science ®Google Scholar
• Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26:1932-40; PMID:17001314; http://dx.doi.org/10.1038/sj.onc.1209990
   PubMed Web of Science ®Google Scholar
• Baumann P, Hagemeier H, Mandl-Weber S, Franke D, Schmidmaier R. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001. Anti-Cancer Drugs 2009; 20:259-66; PMID:19240643; http://dx.doi.org/10.1097/CAD.0b013e328328d18b
   PubMed Web of Science ®Google Scholar
• Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011; 19:58-71; PMID:21215704; http://dx.doi.org/10.1016/j.ccr.2010.10.031
   PubMed Web of Science ®Google Scholar
• Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, Baselga J, Guichard S, Rosen N. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Disc 2011; 1:248-59; PMID:22140653; http://dx.doi.org/10.1158/2159-8290.CD-11-0085
   PubMed Web of Science ®Google Scholar
• Li QL, Gu FM, Wang Z, Jiang JH, Yao LQ, Tan CJ, Huang XY, Ke AW, Dai Z, Fan J, et al. Activation of PI3KAKT and MAPK pathway through a PDGFRbeta-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma. PloS One 2012; 7:e33379; PMID:22428038; http://dx.doi.org/10.1371/journal.pone.0033379
   PubMedGoogle Scholar
• Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, Peterson TR, Choi Y, Gray NS, Yaffe MB, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011; 332:1317-22; PMID:21659604; http://dx.doi.org/10.1126/science.1199498
   PubMed Web of Science ®Google Scholar
• Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villen J, Kubica N, Hoffman GR, Cantley LC, Gygi SP, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011; 332:1322-6; PMID:21659605; http://dx.doi.org/10.1126/science.1199484
   PubMed Web of Science ®Google Scholar
• Rosich L, Montraveta A, Xargay-Torrent S, Lopez-Guerra M, Roldan J, Aymerich M, Salaverria I, Bea S, Campo E, Perez-Galan P, et al. Dual PI3KmTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. Oncotarget 2014; 5:6788-800; PMID:25216518
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501; PMID:12094235; http://dx.doi.org/10.1038/nrc839
   PubMed Web of Science ®Google Scholar
• Passacantilli I, Capurso G, Archibugi L, Calabretta S, Caldarola S, Loreni F, Delle Fave G, Sette C. Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition. Oncotarget 2014; 5:5381-91; PMID:25026292
   PubMed Web of Science ®Google Scholar
• Leontieva OV, Lenzo F, Demidenko ZN, Blagosklonny MV. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells. Cell Cycle 2012; 11:4642-9; PMID:23187803; http://dx.doi.org/10.4161/cc.22937
   PubMed Web of Science ®Google Scholar
• Wang H, Wu R, Yu L, Wu F, Li S, Zhao Y, Li H, Luo G, Wang J, Zhou J. SGEF is overexpressed in prostate cancer and contributes to prostate cancer progression. Oncol Rep 2012; 28:1468-74; PMID:22824926
   PubMed Web of Science ®Google Scholar